Declining Shares, Platform

Tempus AI (NASDAQ:TEM) has experienced a 22.4 % year‑to‑date decline, trading at a price‑to‑sales ratio of 6.4x—below the sector‑adjusted fair value of approximately 7.9x—while remaining unprofitable and under cash‑flow pressure. The company’s latest clinical traction is centered on its Paige Prostate AI platform, which has begun deployment in real‑world settings and is expected to drive future revenue growth.